You might be a bit optimistic on the 'before the fall' comment for getting full enrollment. Otherwise I agree with your point here.
Back in late 2015, they were enrolling a steadily climbing 25-35 patients per month for the main Phase III trial. They did enroll a total of 340 patients during the whole of 2015 though. Assuming they push as hard as their CRO did in that year, I could see enrollment by end of Q1 of 2025 though. Once enrollment is filled - they should have data for an initial phase 1 (lower case intended) readout of their confirmatory trial by (I would guess) the next quarter.
Also, keep in mind, that the confirmatory trial has a more limited pool of patients than did the world-wide trial BECAUSE they are going to focus in on a subset of the potential patients with their confirmatory trail. I was tracking enrollment fairly closely back in 2015 when I still occasionally wrote summaries on Seeking Alpha. Part of how quickly they can fill a new trial is going to depend on how much human and financial capital they have available to throw at the problem.
News 
Market Data 
Discover 
